Tang A, Zak S, Iorio R, et al. - This study was sought to ascertain whether a protocol of 81-mg aspirin (ASA) bis in die (BID) is safe and/or effective in preventing venous thromboembolism (VTE) in patients undergoing revision total hip arthroplasty (rTHA) vs 325-mg ASA BID. A large academic medical center adopted a new protocol for VTE prophylaxis in arthroplasty patients at standard risk in 2017. Initially, 325-mg ASA BID was given to the patients but switched to 81-mg ASA BID. Between 2011 and 2019, researchers carried out a retrospective review to distinguish 1,361 consecutive revision total hip arthroplasty patients and their correlated 90-day postoperative complications such as VTE. Primary endpoints included pulmonary embolism and/or deep vein thrombosis. Gastrointestinal and wound bleeding, acute periprosthetic joint infection, and mortality was considered as the secondary outcome. In this research, 973 rTHAs were conducted and 13 total VTE cases were diagnosed (1.34%) between 2011 to 2017. Evidence showed that in patients undergoing rTHA, applying a protocol of 81-mg of ASA BID is noninferior to 325-mg ASA BID and may be safe and effective in maintaining low rates of VTE.